Clinical and prognostic features of plasmacytomas: A multicenter study of Turkish Oncology Group-Sarcoma Working Party

Simple item page
dc.contributor.authorKilciksiz S.
dc.contributor.authorCelik O.K.
dc.contributor.authorPak Y.
dc.contributor.authorDemiral A.N.
dc.contributor.authorPehlivan M.
dc.contributor.authorOrhan O.
dc.contributor.authorTokatli F.
dc.contributor.authorAgaoglu F.
dc.contributor.authorZincircioglu B.
dc.contributor.authorAtasoy B.M.
dc.contributor.authorOzseker N.
dc.contributor.authorYersal O.
dc.contributor.authorNiang U.
dc.contributor.authorHaydaroglu A.
dc.date.accessioned2024-07-22T08:22:05Z
dc.date.available2024-07-22T08:22:05Z
dc.date.issued2008
dc.description.abstractTo identify the outcomes of prognostic factors of solitary plasmacytoma mainly treated with local radiotherapy (RT). The data were collected from 80 patients with solitary plasmacytoma (SP). Forty patients (50.0%) received radiotherapy (RT) alone while 38 of them (47.5%) were treated with surgery (S) and RT. The median radiation dose was 46 Gy (range 30-64). The median follow up was 2.41 years (range 0.33-12.33). Ten-year overall survival (OS) and local relapse-free survival (LRFS) were 73% and 94%, respectively. The median progression-free survival (PFS) and multiple myeloma-free survival (MMFS) were 3.5 years and 4.8 years, respectively. On multivariate analyses, the favorable factors were radiotherapy dose of >50 Gy and RT + S for PFS and younger age for MMFS. For the patients with medullary plasmacytoma, the favorable factor was younger age for MMFS. RT at ≥50 Gy and RT + S may be favorable prognostic factors on PFS. Younger patients, especially with head-neck lesion and without pre-RT macroscopic tumor, seem to have the best outcome when treated with RT ± S. Progression to MM remains as the main problem especially for older patients. © 2008 Wiley-Liss, Inc.
dc.identifier.DOI-ID10.1002/ajh.21211
dc.identifier.issn10968652
dc.identifier.urihttp://akademikarsiv.cbu.edu.tr:4000/handle/123456789/18920
dc.language.isoEnglish
dc.rightsAll Open Access; Bronze Open Access
dc.subjectAdolescent
dc.subjectAdult
dc.subjectAged
dc.subjectBone Neoplasms
dc.subjectCombined Modality Therapy
dc.subjectDisease Progression
dc.subjectDisease-Free Survival
dc.subjectFemale
dc.subjectFollow-Up Studies
dc.subjectHumans
dc.subjectMale
dc.subjectMiddle Aged
dc.subjectMultiple Myeloma
dc.subjectPlasmacytoma
dc.subjectPrognosis
dc.subjectRadiotherapy Dosage
dc.subjectRisk
dc.subjectSurvival Analysis
dc.subjectTreatment Outcome
dc.subjectTurkey
dc.subjectadolescent
dc.subjectadult
dc.subjectage
dc.subjectaged
dc.subjectarticle
dc.subjectcancer radiotherapy
dc.subjectcancer survival
dc.subjectclinical trial
dc.subjectcornea injury
dc.subjectexcision
dc.subjectfemale
dc.subjectfollow up
dc.subjecthuman
dc.subjectKaplan Meier method
dc.subjectmajor clinical study
dc.subjectmale
dc.subjectmucosa inflammation
dc.subjectmulticenter study
dc.subjectoverall survival
dc.subjectpathologic fracture
dc.subjectplasmacytoma
dc.subjectpriority journal
dc.subjectprognosis
dc.subjectradiation dose
dc.subjectradiation injury
dc.subjectrelapse
dc.subjectretrospective study
dc.subjectstatistical analysis
dc.subjecttumor localization
dc.subjecttumor volume
dc.subjectTurkey (republic)
dc.titleClinical and prognostic features of plasmacytomas: A multicenter study of Turkish Oncology Group-Sarcoma Working Party
dc.typeArticle

Files

Collections

Scopus Koleksiyonu